分子分型尿路上皮肿瘤细胞亚型在转移演化过程中保持稳定
该研究分析了154例尿路上皮癌进展队列中138对匹配的原发肿瘤与远隔转移灶,采用免疫组化及20对样本的mRNA测序,发现基于蛋白的肿瘤细胞亚型在转移过程中保持一致率为94%(95%CI 88-97%),而转录组共识亚型一致性仅45%(95%CI 23-69%),提示免疫组化分型稳定,转录组异质性受间质成分影响。
要点
- 基于蛋白的肿瘤细胞亚型(管腔型、基底型、神经内分泌型)在转移过程中保持稳定,一致率94%。
- 转录组分子共识亚型在原发灶与转移灶间异质性较高,一致率仅45%。
- 间质丰富型肿瘤均显示管腔型肿瘤细胞分化,其基因表达信号受间质成分叠加影响。
核心结论
- 免疫组化可将尿路上皮癌肿瘤细胞分为管腔型、基底型或神经内分泌型,且这些亚型在转移进展过程中保持稳定。
研究设计与样本
- 研究分析了尿路上皮癌进展队列(N=154例患者)中138对匹配的原发肿瘤与同时或异时性远隔转移灶,采用免疫组化检测,并对20对匹配样本进行mRNA测序。
主要发现
- 基于蛋白的肿瘤细胞亚型和组织形态学在转移进展过程中保持稳定,一致率为94%(95%CI 88-97%)。
- 转录组分子共识亚型在原发灶与转移灶之间表现出更高的异质性,一致率为45%(95%CI 23-69%),亚型转换尤其发生在管腔型与间质丰富型肿瘤之间。
- 所有分类为间质丰富型的肿瘤均显示管腔型肿瘤细胞分化。
- 深入分析发现,管腔型基因和蛋白表达与促结缔组织增生性间质含量增加呈负相关。
临床怎么用
- 作者认为这些发现拓展了对尿路上皮癌转移的生物学理解,并对未来转移性尿路上皮癌患者的亚型分层临床试验具有意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Urothelial cancer (UC) care is moving toward precision oncology. For tumor biology-driven treatment of metastatic UC (mUC), molecular subtypes play a crucial role. However, it is not known whether subtypes change during metastatic evolution. To address this, we analyzed a UC progression cohort (N = 154 patients) with 138 matched primary tumors (PRIM) and synchronous or metachronous distant metastasis (MET) by immunohistochemistry, and mRNA sequencing in a subgroup of 20 matched pairs. Protein-based tumor cell subtypes and histomorphology remained stable during metastatic progression (concordance: 94%, 95% confidence interval [CI] 88-97%). In comparison, transcriptome-based molecular consensus subtypes exhibited higher heterogeneity between PRIM and MET (concordance: 45%, 95% CI 23-69%), with switches particularly occurring between luminal and stroma-rich tumors. Of note, all tumors classified as stroma rich showed luminal tumor cell differentiation. By an in-depth analysis, we found a negative correlation of luminal gene and protein expression with increasing desmoplastic stroma content, suggesting that luminal tumor cell differentiation of "stroma-rich tumors" is superimposed by gene expression signals stemming from the stromal compartment. Immunohistochemistry allows tumor cell subtyping into luminal, basal, or neuroendocrine classes that remain stable during metastatic progression. These findings expand our biological understanding of UC MET and have implications for future subtype-stratified clinical trials in patients with mUC. PATIENT SUMMARY: Urothelial carcinomas (UCs) occur in different appearances, the so-called molecular subtypes. These molecular subtypes will gain importance for the therapy of metastatic UCs in the future. We could demonstrate that the subtype remains stable during metastasis, which is highly relevant for future studies.
引用
- Cox A, Klümper N, Stein J, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. 2023. PMID: 37031005. doi:10.1016/j.eururo.2023.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。